pre-IPO PHARMA

COMPANY OVERVIEW

Mozart Therapeutics is focused on developing disease-modifying therapies for autoimmune and inflammatory diseases that work by targeting a novel regulatory immune pathway. The therapeutic focus of Mozart's lead program is autoimmune mediated gastro-intestinal disorders. The company is headquartered in Seattle, WA.


LOCATION


THERAPEUTIC AREAS


WEBSITE

https://www.mozart-tx.com


CAREER WEBSITE

None


SOCIAL MEDIA


INVESTORS


PRESS RELEASES


Jun 21, 2023

Mozart Therapeutics Presents Preclinical Data for MTX-101, a Novel CD8 Treg Network Modulator for Treatment of Autoimmune Disease, at FOCIS 2023 Annual Meeting


Jun 7, 2023

Mozart Therapeutics Raises $25 Million in Expanded Series A Financing to Support Clinical Development of First-in-Class CD8 Treg Modulators for the Treatment of Autoimmune Diseases


May 15, 2023

Mozart Therapeutics Highlights Promising Preclinical Activity of Novel CD8 Treg Network Modulator for Treatment of Autoimmune Diseases in Presentations at IMMUNOLOGY™ 2023


May 18, 2022

Mozart Therapeutics to Present on Novel CD8 T Cell Network at the 2022 Digestive Disease Week (DDW) Conference


May 10, 2022

Mozart Therapeutics Presents Data at IMMUNOLOGYTM 2022 Highlighting Novel CD8 Treg Network in Celiac Disease and Other Autoimmune Diseases


For More Press Releases


Google Analytics Alternative